Increased resting heart rate and prognosis in treatment‐naïve unselected cancer patients: results from a prospective observational study. (23rd March 2020)

• Record Type: Journal Article
• Authors: Anker, Markus S.; Frey, Maria K.; Goliasch, Georg; Bartko, Philipp E.; Prausmüller, Suriya; Gisslinger, Heinz; Kornek, Gabriela; Strunk, Guido; Raderer, Markus; Zielinski, Christoph; Hülsmann, Martin; Pavo, Noemi
• Is Part Of: European journal of heart failure. Volume 22:Number 7(2020)
• Page Start: 1230
• Page End: 1238
• Publication Date: 2020-03-23
• Subjects: Treatment‐naïve cancer patients -- Survival -- Resting heart rate -- Electrocardiogram; Heart failure -- Periodicals; Heart Failure -- Periodicals; Insuffisance cardiaque -- Périodiques; Heart failure; Periodicals; 616.129005
• DOI: 10.1002/ejhf.1782
• Languages: English
• ISSNs: 1388-9842

Abstract

Abstract: Aims: Cancer patients suffer from impaired cardiovascular function. Elevated resting heart rate (RHR) has been identified as a marker for increased long‐term mortality in cancer patients prior to the receipt of anticancer treatment. We aimed to establish whether RHR is associated with survival in treatment‐naïve cancer patients. Methods and results: This prospective study enrolled 548 unselected treatment‐naïve cancer patients between 2011 and 2013. The median age of the cohort was 62 years; 40.9% were male and 32.7% had metastatic disease. Median RHR was 72 b.p.m. Most patients were in sinus rhythm ( n = 507, 92.5%). Clinical heart failure was noted in 37 (6.8%) patients. RHR was not related to cancer stage ( P = 0.504). Patients in the highest RHR tertile had higher levels of high‐sensitivity troponin ( P = 0.003) and N‐terminal pro‐B‐type natriuretic peptide ( P = 0.039). During a median follow‐up of 25 months (interquartile range: 16–32 months; range: 0–40 months), 185 (33.8%) patients died from any cause [1‐year‐mortality: 17%, 95% confidence interval (CI) 13–20%]. In univariate survival analysis, RHR predicted all‐cause mortality [crude hazard ratio (HR) for a 5 b.p.m. increase in RHR: 1.09, 95% CI 1.04–1.15; P < 0.001], and remained significantly associated with outcome after adjustment for age, gender, tumour entity, tumour stage, cardiac status and haemoglobin (adjusted HR for a 5 b.p.m. increase in RHR: 1.10, 95% CI 1.04–1.16; P < 0.001). There was no significant impact of metastatic/non‐metastatic disease state on the predictive value of RHR ( P = 0.433 for interaction). In subgroup analyses, the strongest associations for RHR with mortality were observed in lung (crude HR 1.14; P = 0.007) and gastrointestinal (crude HR 1.31; P < 0.001) cancer. Conclusions: Treatment‐naïve cancer patients with higher RHRs display higher levels of cardiovascular biomarkers. RHR was independently associated with all‐cause mortality, especially in lung and gastrointestinal cancers. Elevated RHR and cardiovascular biomarkers may represent early signs of incipient cardiac dysfunction.